# Cross‐Sectional Analysis of Research and Non‐Research Payments From the Medical Device Industry to Healthcare Professionals and Organisations in Japan in 2022

## TL;DR

This study examines financial payments from Japanese medical device companies to healthcare professionals and organizations in 2022, finding most payments were for non-research purposes.

## Contribution

The study provides the first comprehensive analysis of financial relationships between medical device companies and healthcare stakeholders in Japan.

## Key findings

- Most payments ($186.5 million) were for non-research activities like sponsorships and consulting fees.
- Only 23.9% of payments ($58.7 million) were allocated to research and development.
- Over 80% of companies spent more on non-research activities than on research.

## Abstract

Financial relationships between healthcare professionals (HCPs), healthcare organisations (HCOs) and the medical device industry in Japan may lead to conflicts of interest. Limited transparency in these relationships has raised concerns regarding their potential influence on clinical decision‐making and patient care.

This study aimed to assess the scope and magnitude of financial payments from medical device companies to HCPs and HCOs in Japan, focusing on publicly disclosed data from the 2022 fiscal year.

A cross‐sectional analysis of publicly available payment disclosures from 169 medical device companies, including all members of the Japan Federation of Medical Devices Associations (JFMDA) and several major non‐JFMDA affiliated companies, was conducted. Descriptive statistics were calculated to summarise payment data.

Of the 169 medical device companies, 32.5% (55 companies) did not disclose payment information and 6 companies disclosed payment records in aggregated amounts with their group companies, leaving 108 companies for analysis. In total, $245.2 million in payments were made in 2022, with only 23.9% ($58.7 million) to research and development. Of the total, 34.6% ($84.9 million) was allocated to non‐research payments to HCOs for sponsoring HCOs’ activities, and 19.6% ($49.0 million) were paid for lecturing and consulting fees, typically to individual HCPs. More than 80% of companies allocated a greater share of payments to non‐research activities than to research.

This study reveals substantial financial relationships between medical device companies and HCPs/HCOs in Japan, predominantly for non‐research purposes. Improved transparency regulations, including a uniform, government‐run database, are necessary to better oversee these financial interactions with medical device industry in Japan.